CN101698105A - Gastrointestinal tract contrast medium - Google Patents
Gastrointestinal tract contrast medium Download PDFInfo
- Publication number
- CN101698105A CN101698105A CN200910224879A CN200910224879A CN101698105A CN 101698105 A CN101698105 A CN 101698105A CN 200910224879 A CN200910224879 A CN 200910224879A CN 200910224879 A CN200910224879 A CN 200910224879A CN 101698105 A CN101698105 A CN 101698105A
- Authority
- CN
- China
- Prior art keywords
- contrast medium
- gastrointestinal tract
- iodide
- iodine
- purified water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 53
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 37
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 34
- 239000011630 iodine Substances 0.000 claims abstract description 34
- 239000008213 purified water Substances 0.000 claims abstract description 33
- 229940057995 liquid paraffin Drugs 0.000 claims abstract description 13
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 15
- 239000008369 fruit flavor Substances 0.000 claims description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 235000010489 acacia gum Nutrition 0.000 claims description 5
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 5
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 claims description 5
- 229950005811 sodium amidotrizoate Drugs 0.000 claims description 5
- 235000009518 sodium iodide Nutrition 0.000 claims description 5
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims description 4
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 claims description 4
- 229960002603 iopromide Drugs 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 3
- 229960001025 iohexol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 claims description 2
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 claims description 2
- 229940046413 calcium iodide Drugs 0.000 claims description 2
- 229910001640 calcium iodide Inorganic materials 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- -1 fatty acid iodide Chemical class 0.000 claims description 2
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 abstract description 11
- 210000001015 abdomen Anatomy 0.000 abstract description 7
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 230000003902 lesion Effects 0.000 abstract description 6
- 210000000056 organ Anatomy 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 150000004694 iodide salts Chemical class 0.000 abstract 2
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 19
- 231100000915 pathological change Toxicity 0.000 description 17
- 230000036285 pathological change Effects 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 13
- 230000002496 gastric effect Effects 0.000 description 11
- 229910052788 barium Inorganic materials 0.000 description 10
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 10
- 238000007689 inspection Methods 0.000 description 10
- 230000001804 emulsifying effect Effects 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 229910052688 Gadolinium Inorganic materials 0.000 description 7
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 7
- 230000003187 abdominal effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000002601 radiography Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- PVBALTLWZVEAIO-UHFFFAOYSA-N diodone Chemical compound OC(=O)CN1C=C(I)C(=O)C(I)=C1 PVBALTLWZVEAIO-UHFFFAOYSA-N 0.000 description 2
- 229960001845 diodone Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000029052 metamorphosis Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- XUHXFSYUBXNTHU-UHFFFAOYSA-N Iotrolan Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000009548 contrast radiography Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- 229960003182 iotrolan Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000005408 paramagnetism Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a gastrointestinal tract contrast medium and the contrast medium comprises the following components in parts by weight: 1000 parts of purified water, 0.3-20 parts of one or more of pure iodine and iodides in the purified water, and 1-8 parts of edible liquid paraffin, wherein the weight of iodine and iodides is calculated by 100% of pure iodine. The gastrointestinal tract contrast medium has the advantage that the contrast medium is safe and effective and has no toxic and side effects, the contrast medium can be fast filled in the part of body which is needed to imaged, and the contrast medium filled in the intracavity can form imaging oral contrast medium with a certain threshold specific density on the adjacent organ and lesion (nidus). After drunken, the contrast medium of the invention is not easy to absorb and can be discharged fast; the physiochemical performance of the contrast medium is stable, the comparison is obvious, the image is clear, the effective diagnosis rate reaches above 97%, the detecting ability is excellent especially for the observation of midabdomen, lower abdomen and pelvic cavity and the diagnosis of the small lesion (nidus), and the sensitivity and specificity for detecting early tumors and lesions in the gastrointestinal tract can be increased.
Description
Technical field:
The present invention relates to a kind of gastrointestinal tract contrast medium, be used for the clinical CT of development, MRI abdominal part imaging examination.Subject range: oral or coloclysis was full before abdominal part and pelvic cavity CT, MRI checked prepares, is used for CT, the video picture of MRI gastrointestinal imaging.
Background technology:
Tumor early discovery early treatment is the routine clinical employing methods in present various countries, utilizes CT, MRI tomography technology, and carrying out the gastrointestinal tract imaging diagnosis is International Development research focus.If carry out the contrast agent that CT, MRI gastrointestinal examination then at first will solve full intracavity.
Present clinical gastrointestinal examination is still based on barium meal stomach function regulating, intestinal endoscopy etc., and comparing them with CT, MRI all can't the outer pathological changes of observation chamber, as the infiltration of surrounding organ, and lymphatic metastasis etc.Adopt conventional CT, the scanning of MRI stomach, accurately show lymph node size, position and metamorphosis, the information of metastasis is provided effectively, but can not better show normal coat of the stomach structure and pathological changes, little membrane changing can't be diagnosed especially, and demonstration mucosa that can not be comprehensive and whole itself and pathological changes are closed on the metamorphosis of district's mucosa; As bridge shape mucosal fold etc.Colonoscope is a kind of unusual effective ways of knot rectal mucosa of diagnosing, but checking process is uncomfortable, the patient often need take tranquilizer and analgesic, particularly because the tediously long or narrow sexually transmitted disease (STD) of colon becomes existence, has the patient of 10%-20% can not finish colonoscopy.Though barium coloclysis relative low price, but the intrinsic characteristic of patient's uncomfortable property and projection in the checking process (cause overlapping intestinal song be difficult to assessment) has limited the application of barium coloclysis as the generaI investigation instrument in the past few decades, and it is very high to operator's dependency, between veteran doctor and the general doctor, the focus recall rate differs bigger.
Domestic and international clinical employing contrast agent carries out CT at present, the MRI gastrointestinal examination mainly contains:
1, gadolinium agent: a kind of paramagnetism used for intravenous injection contrast agent, injection is made gadolinium agent aqueous solution after blending the water dilution, be used for the inspection of MRI gastrointestinal imaging after oral administration or the coloclysis.Optium concentration 10mmol/L with gadolinium agent imaging is an example, and the 1.5L gadolinium agent aqueous solution of preparation standard will need the gadolinium agent 30ml of 0.5mol/L, with the calculation of price of domestic market gadolinium agent, needs cost 700-800 unit.Therefore domestic any one tame hospital is difficult to gadolinium agent aqueous solution coloclysis MRC as colorectal carcinoma patient common method.
2, barium sulfate: canel barium meal contrast examination agent, the interior inspection method that under the X line, shows the video picture of digestive tract pathological changes of full gastrointestinal cavity.Gulp down barium or the video picture of barium coloclysis only can be seen gastral profile, and the gastrointestinal image that is full of the barium agent is often covered small focus, therefore often by oral foaming agent or to the intestinal gas injection, make existing highdensity barium agent in the gastrointestinal tract, low-density gas shadow is arranged again, form gas barium contrast radiography, checking process causes positive findings easily.The radiography of barium agent simultaneously can't finish that pathological changes is observed and overlapping intestinal is bent differentiates in the chamber outside, and the patient reflects that generally barium sulfate hypopharynx occurs being difficult to when full and vomits drinking.
3, gasgraphy agent (air or CO
2): be to be used for clinical research in recent years, but never be widely used that reason is exactly that gas has the pseudo-shadow of apparent in view magnetosensitive sense, and in the scanning process, need the patient to hold one's breath 2-5 time,, may cause the position, boundary of gradation scanning misregister to occur if it is discontinuous to hold one's breath.
4, hospital's self-control diodone: employing is blended into the 10%-30% Reno-M with water and makes the method that contrast agent is used for the CT gastrointestinal examination.This method for making comes from 87 years and begins the science introduction that we research and develop contrast agent.Hospital's self-control diodone mouthfeel is poor, lacks contrast standard, and untoward reaction is many, and there is medical safety hidden danger in very easily cross infection disease.
A term electronic computer human body fault imaging (CT), MRT (MRI).
B term gastrointestinal imaging contrast medium medical image/diagnosis auxiliary agent.
A patent application is formerly also arranged at present, a kind of CT gastrointestinal tract contrast medium is disclosed, adopt in this patent application and help cathartic, purpose is for emptying body interimage agent as early as possible and shortens the holdup time, but the shortcoming of this gastrointestinal tract contrast medium is that disease patient should not use for mechanical intestinal obstruction, the intestines and stomach is hemorrhage etc.
Summary of the invention:
The object of the present invention is to provide a kind of safe, effective, side effect is low, can fill the contrast agent that needs radiography position, full intracavity fast and adjoin organ and pathological changes (kitchen range) and form certain threshold comparison density and the oral type contrast agent of video picture.Difficult absorption of this product drink rear intestinal and emptying are fast; Physicochemical property is stable, and the video picture contrast is clear, and the efficient diagnosis rate reaches more than 97%; Especially in, that lower abdomen and the little occupying lesion contrast of pelvic cavity detect ability is superior, can improve sensitivity and specificity that gastrointestinal tract infantile tumour and pathological changes detect.
Purpose of the present invention is implemented by following technical scheme: gastrointestinal tract contrast medium includes forming of following weight portion: in 1000 parts of purified water, contain any or several combinations of the iodine of pure iodine of 0.3-20 part and iodide, wherein iodine and iodide are that 100% pure iodine calculates food grade liquid paraffin 1-8 part by purity.
Described iodine and iodide are water soluble or the iodide that are dissolved in oil.
Described iodide are sodium iodide, potassium iodide, calcium iodide, iodate, amidotrizoic acid, sodium amidotrizoate, cardiografin, iohexol (iohexol), Iopromide (iopromide) and B-15000 (iopamidol), iotrolanvist (iotrolan), fatty acid iodide.
A kind of gastrointestinal tract contrast medium also includes stabilizing agent, and wherein in 1000 parts the purified water, described by weight stabilizing agent is 0.1-1 part.Described stabilizing agent is an arabic gum.
A kind of gastrointestinal tract contrast medium also includes fruit flavors, and wherein in 1000 parts the purified water, described by weight fruit flavors is 0.5-8 part, and described fruit flavors is aspartame, xylitol or sweetener.
Operation principle: the more absorption X line of the present invention's energy, full intracavity contrast agent and surrounding tissue organ form the density contrast and video picture under X-ray.Medical practitioner is by contrast images, to digestive tract with adjoin organ and carry out that pathological changes is observed and diagnostic comments is made in discriminating.
Advantage of the present invention: transparency liquid, mouthfeel is good, and side effect is low, does not have taboo, and contrast agent can fill fast needs the radiography position.Physicochemical property is stable, contrast obviously, clear picture is beneficial to the doctor and observes and differentiate little pathological changes (kitchen range), especially in, that lower abdomen and pelvic cavity pathological changes detect ability is superior.Emptying is quick, and liquid paraffin acts on mainly that to impel the intestines and stomach not absorb in line, utilizes paraffin to be difficult for by the gastrointestinal absorption characteristic, and short its contrast agent arrives fast and examined the position, can reduce doctors and patients' waiting time to be checked.The present invention fills up CT gastrointestinal examination application blank, for doctor, patient start new diagnostic mode.Differentiating in the imaging, clear picture, contrast obviously, the doctor to the shallow pathological changes, that little occupying lesion detects ability is superior, can improve sensitivity and specificity that gastrointestinal tract infantile tumour and pathological changes detect.
The specific embodiment:
Embodiment 1: prepare a kind of gastrointestinal tract contrast medium, wherein get 1000 kilograms of purified water, get mass percent and be 0.31 kilogram of 98% iodine (is that 100% pure iodine is calculated as 0.3 kilogram pure iodine by purity), get 1 kilogram food grade liquid paraffin.Preparing process: accurately measure each raw-material quality, fully dissolve the back with a small amount of purified water and mix, be diluted to the necessary requirement volume, carry out ultra-clean after the emulsifying and filter, sterilization, packing with purified water.
Embodiment 2: prepare a kind of gastrointestinal tract contrast medium, wherein get 1000 kilograms of purified water, get mass percent and be 0.2 kilogram of 98% 0.2 kilogram of 0.3 kilogram of iodine, sodium iodide, sodium iodate (is that 100% pure iodine is calculated as 0.59 kilogram pure iodine by purity), get 3 kilograms food grade liquid paraffin.Preparing process: accurately measure each raw-material quality, fully dissolve the back with a small amount of purified water and mix, be diluted to the necessary requirement volume, carry out ultra-clean after the emulsifying and filter, sterilization, packing with purified water.
Embodiment 3: prepare a kind of gastrointestinal tract contrast medium, wherein get 1000 kilograms of purified water, get mass percent and be 0.6 kilogram of 98% 0.1 kilogram of 0.3 kilogram of iodine, sodium amidotrizoate, cardiografin (is that 100% pure iodine is calculated as 0.64 kilogram pure iodine by purity), get 5 kilograms food grade liquid paraffin.Preparing process: accurately measure each raw-material quality, fully dissolve the back with a small amount of purified water and mix, be diluted to the necessary requirement volume, carry out ultra-clean after the emulsifying and filter, sterilization, packing with purified water.
Embodiment 4: prepare a kind of gastrointestinal tract contrast medium, wherein get 1000 kilograms of purified water, get 0.4 kilogram of 0.4 kilogram of sodium iodide, potassium iodide (is that 100% pure iodine is calculated as 0.64 kilogram pure iodine by purity), get 4 kilograms food grade liquid paraffin.Preparing process: accurately measure each raw-material quality, fully dissolve the back with a small amount of purified water and mix, be diluted to the necessary requirement volume, carry out ultra-clean after the emulsifying and filter, sterilization, packing with purified water.
Embodiment 5: prepare a kind of gastrointestinal tract contrast medium, wherein get 1000 kilograms of purified water, (0.6 kilogram of 300mg iodine/ml) 0.5 kilogram, iotrolanvist (is that 100% pure iodine is calculated as 0.43 kilogram pure iodine by purity) are got 3 kilograms food grade liquid paraffin to get B-15000.Preparing process: accurately measure each raw-material quality, fully dissolve the back with a small amount of purified water and mix, be diluted to the necessary requirement volume, carry out ultra-clean after the emulsifying and filter, sterilization, packing with purified water.
Embodiment 6: prepare a kind of gastrointestinal tract contrast medium, wherein get 1000 kilograms of purified water, (0.6 kilogram of 300mg iodine/ml) 0.5 kilogram, iotrolanvist (is that 100% pure iodine is calculated as 0.43 kilogram pure iodine by purity) are got 3 kilograms food grade liquid paraffin to get Iopromide.Preparing process: accurately measure each raw-material quality, fully dissolve the back with a small amount of purified water and mix, be diluted to the necessary requirement volume, carry out ultra-clean after the emulsifying and filter, sterilization, packing with purified water.
Embodiment 7: prepare a kind of gastrointestinal tract contrast medium, wherein get 1000 kilograms of purified water, 29.7 kilograms of 10 kilograms of sodium amidotrizoate, cardiografin (is that 100% pure iodine is calculated as 20 kilograms pure iodine by purity), get 8 kilograms food grade liquid paraffin, get 1 kilogram arabic gum, get 5 kilograms fruit flavors, fruit flavors can be aspartame.Preparing process: accurately measure each raw-material quality, fully dissolve the back with a small amount of purified water and mix, be diluted to the necessary requirement volume, carry out ultra-clean after the emulsifying and filter, sterilization, packing with purified water.
Embodiment 8: prepare a kind of gastrointestinal tract contrast medium, wherein get 1000 kilograms of purified water, 15 kilograms of 6 kilograms of sodium amidotrizoate, cardiografin (is that 100% pure iodine is calculated as 10.66 kilograms pure iodine by purity), get 6 kilograms food grade liquid paraffin, get 0.5 kilogram arabic gum, get 3 kilograms fruit flavors, fruit flavors can be xylitol.Preparing process: accurately measure each raw-material quality, fully dissolve the back with a small amount of purified water and mix, be diluted to the necessary requirement volume, carry out ultra-clean after the emulsifying and filter, sterilization, packing with purified water.
Embodiment 9: prepare a kind of gastrointestinal tract contrast medium, wherein get 1000 kilograms of purified water, get 0.5 kilogram of 0.51 kilogram of sodium iodide, potassium iodide (is that 100% pure iodine is calculated as 0.81 kilogram pure iodine by purity), get 2 kilograms food grade liquid paraffin, get 0.1 kilogram arabic gum, get 0.5 kilogram fruit flavors, fruit flavors can be sweetener.Preparing process: accurately measure each raw-material quality, fully dissolve the back with a small amount of purified water and mix, be diluted to the necessary requirement volume, carry out ultra-clean after the emulsifying and filter, sterilization, packing with purified water.
Pharmacodynamics embodiment:
The performance indications of the gastrointestinal tract contrast medium that obtains according to embodiment 1-9:
1, sense organ state: colourless transparent liquid.
2, TPER: the inspection in 20 minutes of harmonization of the stomach upper abdomen, lower abdomen and inspection in pelvic cavity 45-50 minute.
3, reduced density: even, the anti-pH value of 256 ± 67Hu video picture density is no pseudo-shadow down.
Clinical verification: (with ten thousand routine tracing records)
1, untoward reaction: oral back person under inspection stomachache, diarrhoea occur, feels sick in one week, vomiting and General Symptoms.Safe and reliable untoward reaction, the efficient and convenient no pain of patient process, the biological assessment: no sensitization, no mucous membrane irritation, the no abnormal variation of histopathological examination etc. do not found.
2, toleration: all the person under inspection thinks that all the product taste is fragrant and sweet, makes the full ideal effect that reaches.
3, arrive terminal ileum: the contrast agent emptying is difficult for absorbing dynamically down at intestinal, and oral back 45-50 ± 5 minutes product arrives or by terminal ileum, can obviously shorten the time before the patient, improves checking efficiency.
4, contrast medium distributes: person under inspection's abdominal part small intestinal product of accepting the abdominal CT inspection is evenly distributed; Person under inspection's pelvic cavity small intestinal product of accepting the pelvic cavity CT examination is evenly distributed; Person under inspection's abdomen group and the basin group small intestinal product of accepting abdomen pelvic cavity CT examination are evenly distributed.
5, the contrast of contrast medium and surrounding tissue: gastrointestinal tract imaging key is to need the favorable tissue contrast or the contrast medium of gastrointestinal tract intracavity and the density contrast of gastrointestinal tract wall to reach certain threshold value clinically.Pseudo-shadow does not appear in CT value 256 ± 67Hu fine demonstration gastrointestinal tract wall of energy and soft tissue piece shadow.
6, density contrast: the imaging key of clinical gastrointestinal tract image is that contrast agent needs the favorable tissue contrast, and the contrast agent of intracavity and the density contrast of gastrointestinal tract wall reach certain threshold value.This contrast agent determines that with vast amount of clinical best reduced density is CT value 256 ± 67Hu.The contrast of this contrast agent down can clear demonstration gastrointestinal tract wall and soft tissue piece shadow, exposes cryptomorphic little pathological changes focus in Zou's wall easily, is convenient to radiate the doctor pathological changes details is observed and discriminating.Reduced density is uniform and stable, and adopt double blinding to observe down: video picture is clear, does not have pseudo-shadow.Can improve the accuracy by stages of the recall rate and the gastrointestinal cancer of gastrointestinal tract early lesion, and the pathological changes that can show the outer abdominal viscera of gastrointestinal tract, especially it is superior shallow pathological changes and little pathological changes (kitchen range) to be detected ability, can allow the doctor increase the confidence and the confidence of correct diagnosis.
Claims (7)
1. gastrointestinal tract contrast medium, it is characterized in that, it includes the composition of following weight portion: in 1000 parts of purified water, contain any or several combinations of the iodine of pure iodine of 0.3-20 part and iodide, wherein iodine and iodide are for being that 100% pure iodine calculates food grade liquid paraffin 1-8 part by purity.
2. a kind of gastrointestinal tract contrast medium according to claim 1 is characterized in that, described iodine and iodide are water soluble or the iodide that are dissolved in oil.
3. a kind of gastrointestinal tract contrast medium according to claim 2, it is characterized in that described iodide are sodium iodide, potassium iodide, calcium iodide, iodate, amidotrizoic acid, sodium amidotrizoate, cardiografin, iohexol, Iopromide, B-15000, iotrolanvist or fatty acid iodide.
4. a kind of gastrointestinal tract contrast medium according to claim 1 is characterized in that it also includes stabilizing agent, and described by weight stabilizing agent is 0.1-1 part.
5. a kind of gastrointestinal tract contrast medium according to claim 4 is characterized in that, described stabilizing agent is an arabic gum.
6. a kind of gastrointestinal tract contrast medium according to claim 1 and 2 is characterized in that it also includes fruit flavors, and described by weight fruit flavors is 0.5-8 part.
7. a kind of gastrointestinal tract contrast medium according to claim 6 is characterized in that, described fruit flavors is aspartame, xylitol or sweetener.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102248797A CN101698105B (en) | 2009-11-23 | 2009-11-23 | Gastrointestinal tract contrast medium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102248797A CN101698105B (en) | 2009-11-23 | 2009-11-23 | Gastrointestinal tract contrast medium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101698105A true CN101698105A (en) | 2010-04-28 |
| CN101698105B CN101698105B (en) | 2012-02-22 |
Family
ID=42146571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102248797A Active CN101698105B (en) | 2009-11-23 | 2009-11-23 | Gastrointestinal tract contrast medium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101698105B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770913A (en) * | 2016-03-25 | 2016-07-20 | 上海世正医学影像诊断中心有限公司 | Compound meglumine diatrizoate injection and use method thereof |
| CN107115534A (en) * | 2017-05-27 | 2017-09-01 | 山东赛克赛斯生物科技有限公司 | A kind of intestines and stomach diagnostic imaging imaging assistant and preparation method thereof |
| CN114288427A (en) * | 2022-03-01 | 2022-04-08 | 福建宸润生物科技有限公司 | Gastrointestinal tract oral CT contrast agent |
| CN114652902A (en) * | 2022-03-10 | 2022-06-24 | 上海市第六人民医院 | 3D printing intravascular absorbable stent visualized under X-ray and preparation method thereof |
| CN115192736A (en) * | 2022-08-22 | 2022-10-18 | 内蒙古爱众医学影像有限公司 | Coal-made light white oil nano-emulsion type low-density contrast agent and preparation method thereof |
-
2009
- 2009-11-23 CN CN2009102248797A patent/CN101698105B/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770913A (en) * | 2016-03-25 | 2016-07-20 | 上海世正医学影像诊断中心有限公司 | Compound meglumine diatrizoate injection and use method thereof |
| CN107115534A (en) * | 2017-05-27 | 2017-09-01 | 山东赛克赛斯生物科技有限公司 | A kind of intestines and stomach diagnostic imaging imaging assistant and preparation method thereof |
| CN114288427A (en) * | 2022-03-01 | 2022-04-08 | 福建宸润生物科技有限公司 | Gastrointestinal tract oral CT contrast agent |
| CN114652902A (en) * | 2022-03-10 | 2022-06-24 | 上海市第六人民医院 | 3D printing intravascular absorbable stent visualized under X-ray and preparation method thereof |
| CN115192736A (en) * | 2022-08-22 | 2022-10-18 | 内蒙古爱众医学影像有限公司 | Coal-made light white oil nano-emulsion type low-density contrast agent and preparation method thereof |
| CN115192736B (en) * | 2022-08-22 | 2023-08-15 | 内蒙古爱众医学影像有限公司 | Coal light white oil nanoemulsion type low-density contrast agent and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101698105B (en) | 2012-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sanderson et al. | Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. | |
| Gupta et al. | Imaging of congenital anomalies of the gastrointestinal tract | |
| CN101698105B (en) | Gastrointestinal tract contrast medium | |
| EP1976520B1 (en) | Kit comprising an osmotic laxative and a stimulant laxative for preparing the colon for virtual colonoscopy | |
| Wang et al. | Enhanced CT and CT virtual endoscopy in diagnosis of heterotopic pancreas | |
| Folvik et al. | Hydrosonography of the small intestine: comparison with radiologic barium study | |
| Kreel et al. | Technique of the double contrast barium meal with examples of correlation with endoscopy | |
| WO2020186804A1 (en) | Gastrointestinal ultrasonographic developer and preparation method therefor | |
| Tolan et al. | Optimization of CT colonography technique: a practical guide | |
| Landeras et al. | Virtual colonoscopy: technique and accuracy | |
| US7378081B2 (en) | Composition and method for direct visualization of the human appendix | |
| Wang et al. | Contrast-enhanced ultrasound using SonoVue mixed with oral gastrointestinal contrast agent to evaluate esophageal hiatal hernia: Report of three cases and a literature review | |
| US20130052143A1 (en) | Liquid preparation for oral administration to be used in ct colonography, and composition for digestive tract imaging | |
| Keum et al. | Intestinal obstruction caused by a duplication cyst of the cecum in a neonate | |
| US20220401587A1 (en) | Low x-ray attenuation change hard shelled oral contrast material | |
| JP5696326B2 (en) | CT colonography test medicine | |
| Kang et al. | Evaluation of a dual-purpose contrast medium for radiography and ultrasonography of the small intestine in dogs | |
| Erdem et al. | Intrapancreatic lipoma and Morgagni hernia: a previously unrecognized association | |
| Kalane et al. | Silent Tachypnoea in a Neonate: A Rare Presentation of Right Side Bochdalek Hernia with Intrathoracic Kidney | |
| CN111166897A (en) | Sonoweiwei compound contrast agent and application | |
| Wang | A Case of Intestinal Obstruction Caused by Barium Retention after Small Bowel Radiography with Barium Meal | |
| Sementsov et al. | MAGNETIC RESONANCE IMAGING OF THE LARGE AND SMALL INTESTINES | |
| Alamdaran | Diagnosis of colorectal polyps by hydrocolonic sonography in children with rectal bleeding | |
| Jamis-Muvdi | Giant cyst of the common bile duct: Preoperative visualization by transhepatic cholangiography in 2 cases | |
| Khashab et al. | Forestier disease: a rare cause of dysphagia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: INNER MONGOLIA AIZHONG MEDICAL IMAGING CO., LTD. Free format text: FORMER OWNER: HOU SHUJUN Effective date: 20141016 Free format text: FORMER OWNER: PENG WEIJUN TIAN CUN Effective date: 20141016 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20141016 Address after: 010051 No. 214 West Hailar Road, Hui District, Hohhot, the Inner Mongolia Autonomous Region Patentee after: Inner Mongolia love medical imaging Co., Ltd. Address before: 010051 No. 214 West Hailar Road, Hohhot Hui Autonomous Region, the Inner Mongolia Autonomous Region Patentee before: Hou Shujun Patentee before: Peng Weijun Patentee before: Tian Cun |